nodes	percent_of_prediction	percent_of_DWPC	metapath
Methadone—Tamoxifen—pancreatic cancer	0.45	1	CrCtD
Methadone—Levomethadyl Acetate—Tamoxifen—pancreatic cancer	0.0276	0.11	CrCrCtD
Methadone—Methadyl Acetate—Tamoxifen—pancreatic cancer	0.0276	0.11	CrCrCtD
Methadone—Loperamide—Tamoxifen—pancreatic cancer	0.0276	0.11	CrCrCtD
Methadone—Doxylamine—Tamoxifen—pancreatic cancer	0.0238	0.0952	CrCrCtD
Methadone—CYP19A1—Tamoxifen—pancreatic cancer	0.0232	0.0996	CbGbCtD
Methadone—Dextropropoxyphene—Tamoxifen—pancreatic cancer	0.0226	0.0905	CrCrCtD
Methadone—Phenoxybenzamine—Tamoxifen—pancreatic cancer	0.0226	0.0905	CrCrCtD
Methadone—Tripelennamine—Tamoxifen—pancreatic cancer	0.0216	0.0862	CrCrCtD
Methadone—Clofedanol—Tamoxifen—pancreatic cancer	0.0164	0.0654	CrCrCtD
Methadone—Benzphetamine—Tamoxifen—pancreatic cancer	0.0158	0.0633	CrCrCtD
Methadone—Orphenadrine—Tamoxifen—pancreatic cancer	0.0158	0.0633	CrCrCtD
Methadone—Benzyl Benzoate—Tamoxifen—pancreatic cancer	0.0147	0.0586	CrCrCtD
Methadone—Diphenhydramine—Tamoxifen—pancreatic cancer	0.0141	0.0562	CrCrCtD
Methadone—CYP3A7—Tamoxifen—pancreatic cancer	0.01	0.0431	CbGbCtD
Methadone—CYP3A7-CYP3A51P—Tamoxifen—pancreatic cancer	0.01	0.0431	CbGbCtD
Methadone—CYP2B6—Tamoxifen—pancreatic cancer	0.00956	0.0411	CbGbCtD
Methadone—CYP3A7—Irinotecan—pancreatic cancer	0.00771	0.0331	CbGbCtD
Methadone—CYP3A7-CYP3A51P—Irinotecan—pancreatic cancer	0.00771	0.0331	CbGbCtD
Methadone—CYP3A5—Tamoxifen—pancreatic cancer	0.00753	0.0324	CbGbCtD
Methadone—CYP2B6—Irinotecan—pancreatic cancer	0.00734	0.0315	CbGbCtD
Methadone—CYP2C8—Tamoxifen—pancreatic cancer	0.00724	0.0311	CbGbCtD
Methadone—CYP1A2—Dacarbazine—pancreatic cancer	0.00705	0.0303	CbGbCtD
Methadone—CYP3A5—Erlotinib—pancreatic cancer	0.0064	0.0275	CbGbCtD
Methadone—CYP2C8—Erlotinib—pancreatic cancer	0.00616	0.0265	CbGbCtD
Methadone—CYP2C19—Tamoxifen—pancreatic cancer	0.00608	0.0261	CbGbCtD
Methadone—CYP3A5—Irinotecan—pancreatic cancer	0.00578	0.0249	CbGbCtD
Methadone—CYP3A7—Docetaxel—pancreatic cancer	0.00565	0.0243	CbGbCtD
Methadone—CYP3A7-CYP3A51P—Docetaxel—pancreatic cancer	0.00565	0.0243	CbGbCtD
Methadone—CYP3A7—Sunitinib—pancreatic cancer	0.00562	0.0242	CbGbCtD
Methadone—CYP3A7-CYP3A51P—Sunitinib—pancreatic cancer	0.00562	0.0242	CbGbCtD
Methadone—CYP1A2—Tamoxifen—pancreatic cancer	0.00561	0.0241	CbGbCtD
Methadone—CYP2C8—Fluorouracil—pancreatic cancer	0.00534	0.0229	CbGbCtD
Methadone—CYP2C9—Tamoxifen—pancreatic cancer	0.00505	0.0217	CbGbCtD
Methadone—ABCB1—Tamoxifen—pancreatic cancer	0.0049	0.0211	CbGbCtD
Methadone—CYP1A2—Erlotinib—pancreatic cancer	0.00477	0.0205	CbGbCtD
Methadone—CYP2D6—Tamoxifen—pancreatic cancer	0.00462	0.0198	CbGbCtD
Methadone—CYP3A5—Docetaxel—pancreatic cancer	0.00424	0.0182	CbGbCtD
Methadone—ABCB1—Gemcitabine—pancreatic cancer	0.00422	0.0181	CbGbCtD
Methadone—CYP3A5—Sunitinib—pancreatic cancer	0.00422	0.0181	CbGbCtD
Methadone—ABCB1—Erlotinib—pancreatic cancer	0.00417	0.0179	CbGbCtD
Methadone—CYP1A2—Fluorouracil—pancreatic cancer	0.00413	0.0178	CbGbCtD
Methadone—CYP2B6—Doxorubicin—pancreatic cancer	0.00401	0.0172	CbGbCtD
Methadone—CYP2D6—Erlotinib—pancreatic cancer	0.00393	0.0169	CbGbCtD
Methadone—ABCB1—Irinotecan—pancreatic cancer	0.00376	0.0162	CbGbCtD
Methadone—CYP2C9—Fluorouracil—pancreatic cancer	0.00372	0.016	CbGbCtD
Methadone—CYP3A4—Tamoxifen—pancreatic cancer	0.00294	0.0126	CbGbCtD
Methadone—ABCB1—Docetaxel—pancreatic cancer	0.00276	0.0119	CbGbCtD
Methadone—ABCB1—Sunitinib—pancreatic cancer	0.00275	0.0118	CbGbCtD
Methadone—HTR3A—enteric nervous system—pancreatic cancer	0.00251	0.637	CbGeAlD
Methadone—CYP3A4—Erlotinib—pancreatic cancer	0.0025	0.0107	CbGbCtD
Methadone—CYP3A4—Irinotecan—pancreatic cancer	0.00226	0.00969	CbGbCtD
Methadone—ABCB1—Doxorubicin—pancreatic cancer	0.00206	0.00884	CbGbCtD
Methadone—CYP2D6—Doxorubicin—pancreatic cancer	0.00194	0.00833	CbGbCtD
Methadone—CYP3A4—Docetaxel—pancreatic cancer	0.00165	0.0071	CbGbCtD
Methadone—CYP3A4—Sunitinib—pancreatic cancer	0.00165	0.00707	CbGbCtD
Methadone—CYP3A4—Doxorubicin—pancreatic cancer	0.00123	0.00529	CbGbCtD
Methadone—HTR3A—islet of Langerhans—pancreatic cancer	0.000239	0.0608	CbGeAlD
Methadone—CYP2C18—digestive system—pancreatic cancer	0.000214	0.0543	CbGeAlD
Methadone—HTR3A—digestive system—pancreatic cancer	0.000144	0.0365	CbGeAlD
Methadone—CYP3A5—islet of Langerhans—pancreatic cancer	0.000119	0.0303	CbGeAlD
Methadone—CYP2C19—digestive system—pancreatic cancer	9.08e-05	0.0231	CbGeAlD
Methadone—Hypersensitivity—Tamoxifen—pancreatic cancer	8.98e-05	0.00196	CcSEcCtD
Methadone—Pain—Sunitinib—pancreatic cancer	8.93e-05	0.00195	CcSEcCtD
Methadone—Constipation—Sunitinib—pancreatic cancer	8.93e-05	0.00195	CcSEcCtD
Methadone—Phlebitis—Doxorubicin—pancreatic cancer	8.76e-05	0.00191	CcSEcCtD
Methadone—Asthenia—Tamoxifen—pancreatic cancer	8.74e-05	0.00191	CcSEcCtD
Methadone—Convulsion—Fluorouracil—pancreatic cancer	8.74e-05	0.00191	CcSEcCtD
Methadone—Confusional state—Irinotecan—pancreatic cancer	8.67e-05	0.00189	CcSEcCtD
Methadone—Asthenia—Erlotinib—pancreatic cancer	8.65e-05	0.00189	CcSEcCtD
Methadone—Pruritus—Tamoxifen—pancreatic cancer	8.62e-05	0.00188	CcSEcCtD
Methadone—Anaphylactic shock—Irinotecan—pancreatic cancer	8.6e-05	0.00187	CcSEcCtD
Methadone—Oedema—Irinotecan—pancreatic cancer	8.6e-05	0.00187	CcSEcCtD
Methadone—Gastrointestinal pain—Sunitinib—pancreatic cancer	8.54e-05	0.00186	CcSEcCtD
Methadone—Pruritus—Erlotinib—pancreatic cancer	8.53e-05	0.00186	CcSEcCtD
Methadone—Shock—Irinotecan—pancreatic cancer	8.46e-05	0.00184	CcSEcCtD
Methadone—Thrombocytopenia—Irinotecan—pancreatic cancer	8.42e-05	0.00184	CcSEcCtD
Methadone—CYP3A5—pancreas—pancreatic cancer	8.38e-05	0.0213	CbGeAlD
Methadone—Anaphylactic shock—Gemcitabine—pancreatic cancer	8.38e-05	0.00183	CcSEcCtD
Methadone—Oedema—Gemcitabine—pancreatic cancer	8.38e-05	0.00183	CcSEcCtD
Methadone—Cardiac failure—Epirubicin—pancreatic cancer	8.36e-05	0.00182	CcSEcCtD
Methadone—Diarrhoea—Tamoxifen—pancreatic cancer	8.34e-05	0.00182	CcSEcCtD
Methadone—Hyperhidrosis—Irinotecan—pancreatic cancer	8.31e-05	0.00181	CcSEcCtD
Methadone—Confusional state—Fluorouracil—pancreatic cancer	8.3e-05	0.00181	CcSEcCtD
Methadone—Body temperature increased—Sunitinib—pancreatic cancer	8.25e-05	0.0018	CcSEcCtD
Methadone—Abdominal pain—Sunitinib—pancreatic cancer	8.25e-05	0.0018	CcSEcCtD
Methadone—Diarrhoea—Erlotinib—pancreatic cancer	8.25e-05	0.0018	CcSEcCtD
Methadone—Anaphylactic shock—Fluorouracil—pancreatic cancer	8.24e-05	0.0018	CcSEcCtD
Methadone—Oedema—Fluorouracil—pancreatic cancer	8.24e-05	0.0018	CcSEcCtD
Methadone—Thrombocytopenia—Gemcitabine—pancreatic cancer	8.2e-05	0.00179	CcSEcCtD
Methadone—Anorexia—Irinotecan—pancreatic cancer	8.2e-05	0.00179	CcSEcCtD
Methadone—Hyperhidrosis—Gemcitabine—pancreatic cancer	8.1e-05	0.00177	CcSEcCtD
Methadone—Thrombocytopenia—Fluorouracil—pancreatic cancer	8.06e-05	0.00176	CcSEcCtD
Methadone—Visual impairment—Docetaxel—pancreatic cancer	8.06e-05	0.00176	CcSEcCtD
Methadone—Dizziness—Tamoxifen—pancreatic cancer	8.06e-05	0.00176	CcSEcCtD
Methadone—Tachycardia—Fluorouracil—pancreatic cancer	8.04e-05	0.00175	CcSEcCtD
Methadone—Hypotension—Irinotecan—pancreatic cancer	8.03e-05	0.00175	CcSEcCtD
Methadone—Anorexia—Gemcitabine—pancreatic cancer	7.98e-05	0.00174	CcSEcCtD
Methadone—Dizziness—Erlotinib—pancreatic cancer	7.97e-05	0.00174	CcSEcCtD
Methadone—Anorexia—Fluorouracil—pancreatic cancer	7.85e-05	0.00171	CcSEcCtD
Methadone—Hypotension—Gemcitabine—pancreatic cancer	7.83e-05	0.00171	CcSEcCtD
Methadone—Insomnia—Irinotecan—pancreatic cancer	7.78e-05	0.0017	CcSEcCtD
Methadone—Flushing—Docetaxel—pancreatic cancer	7.76e-05	0.00169	CcSEcCtD
Methadone—Cardiac arrest—Epirubicin—pancreatic cancer	7.76e-05	0.00169	CcSEcCtD
Methadone—Vomiting—Tamoxifen—pancreatic cancer	7.75e-05	0.00169	CcSEcCtD
Methadone—Cardiac failure—Doxorubicin—pancreatic cancer	7.73e-05	0.00169	CcSEcCtD
Methadone—Hypotension—Fluorouracil—pancreatic cancer	7.7e-05	0.00168	CcSEcCtD
Methadone—Hypersensitivity—Sunitinib—pancreatic cancer	7.69e-05	0.00168	CcSEcCtD
Methadone—Rash—Tamoxifen—pancreatic cancer	7.68e-05	0.00168	CcSEcCtD
Methadone—Dermatitis—Tamoxifen—pancreatic cancer	7.68e-05	0.00167	CcSEcCtD
Methadone—Vomiting—Erlotinib—pancreatic cancer	7.67e-05	0.00167	CcSEcCtD
Methadone—Somnolence—Irinotecan—pancreatic cancer	7.64e-05	0.00167	CcSEcCtD
Methadone—Headache—Tamoxifen—pancreatic cancer	7.64e-05	0.00166	CcSEcCtD
Methadone—Rash—Erlotinib—pancreatic cancer	7.6e-05	0.00166	CcSEcCtD
Methadone—Dermatitis—Erlotinib—pancreatic cancer	7.6e-05	0.00166	CcSEcCtD
Methadone—Insomnia—Gemcitabine—pancreatic cancer	7.58e-05	0.00165	CcSEcCtD
Methadone—Headache—Erlotinib—pancreatic cancer	7.55e-05	0.00165	CcSEcCtD
Methadone—Chills—Docetaxel—pancreatic cancer	7.51e-05	0.00164	CcSEcCtD
Methadone—Asthenia—Sunitinib—pancreatic cancer	7.49e-05	0.00163	CcSEcCtD
Methadone—Decreased appetite—Irinotecan—pancreatic cancer	7.47e-05	0.00163	CcSEcCtD
Methadone—Arrhythmia—Docetaxel—pancreatic cancer	7.47e-05	0.00163	CcSEcCtD
Methadone—Orthostatic hypotension—Epirubicin—pancreatic cancer	7.45e-05	0.00162	CcSEcCtD
Methadone—Insomnia—Fluorouracil—pancreatic cancer	7.45e-05	0.00162	CcSEcCtD
Methadone—Somnolence—Gemcitabine—pancreatic cancer	7.45e-05	0.00162	CcSEcCtD
Methadone—Hypokalaemia—Epirubicin—pancreatic cancer	7.42e-05	0.00162	CcSEcCtD
Methadone—CYP1A2—digestive system—pancreatic cancer	7.42e-05	0.0188	CbGeAlD
Methadone—Pruritus—Sunitinib—pancreatic cancer	7.39e-05	0.00161	CcSEcCtD
Methadone—Constipation—Irinotecan—pancreatic cancer	7.35e-05	0.0016	CcSEcCtD
Methadone—Pain—Irinotecan—pancreatic cancer	7.35e-05	0.0016	CcSEcCtD
Methadone—Somnolence—Fluorouracil—pancreatic cancer	7.32e-05	0.0016	CcSEcCtD
Methadone—Nasopharyngitis—Epirubicin—pancreatic cancer	7.29e-05	0.00159	CcSEcCtD
Methadone—Erythema—Docetaxel—pancreatic cancer	7.28e-05	0.00159	CcSEcCtD
Methadone—Decreased appetite—Gemcitabine—pancreatic cancer	7.28e-05	0.00159	CcSEcCtD
Methadone—Nausea—Tamoxifen—pancreatic cancer	7.24e-05	0.00158	CcSEcCtD
Methadone—Cardiac arrest—Doxorubicin—pancreatic cancer	7.18e-05	0.00156	CcSEcCtD
Methadone—Constipation—Gemcitabine—pancreatic cancer	7.16e-05	0.00156	CcSEcCtD
Methadone—Pain—Gemcitabine—pancreatic cancer	7.16e-05	0.00156	CcSEcCtD
Methadone—Nausea—Erlotinib—pancreatic cancer	7.16e-05	0.00156	CcSEcCtD
Methadone—Decreased appetite—Fluorouracil—pancreatic cancer	7.16e-05	0.00156	CcSEcCtD
Methadone—CYP3A5—digestive system—pancreatic cancer	7.16e-05	0.0182	CbGeAlD
Methadone—Diarrhoea—Sunitinib—pancreatic cancer	7.14e-05	0.00156	CcSEcCtD
Methadone—CYP2B6—digestive system—pancreatic cancer	7.11e-05	0.0181	CbGeAlD
Methadone—Feeling abnormal—Irinotecan—pancreatic cancer	7.09e-05	0.00155	CcSEcCtD
Methadone—Pain—Fluorouracil—pancreatic cancer	7.04e-05	0.00154	CcSEcCtD
Methadone—CYP2C9—digestive system—pancreatic cancer	7.04e-05	0.0179	CbGeAlD
Methadone—Gastrointestinal pain—Irinotecan—pancreatic cancer	7.03e-05	0.00153	CcSEcCtD
Methadone—Muscle spasms—Docetaxel—pancreatic cancer	7e-05	0.00153	CcSEcCtD
Methadone—Dizziness—Sunitinib—pancreatic cancer	6.9e-05	0.00151	CcSEcCtD
Methadone—Feeling abnormal—Gemcitabine—pancreatic cancer	6.9e-05	0.00151	CcSEcCtD
Methadone—Orthostatic hypotension—Doxorubicin—pancreatic cancer	6.89e-05	0.0015	CcSEcCtD
Methadone—Hypokalaemia—Doxorubicin—pancreatic cancer	6.87e-05	0.0015	CcSEcCtD
Methadone—Body temperature increased—Irinotecan—pancreatic cancer	6.8e-05	0.00148	CcSEcCtD
Methadone—Abdominal pain—Irinotecan—pancreatic cancer	6.8e-05	0.00148	CcSEcCtD
Methadone—Feeling abnormal—Fluorouracil—pancreatic cancer	6.79e-05	0.00148	CcSEcCtD
Methadone—Nasopharyngitis—Doxorubicin—pancreatic cancer	6.75e-05	0.00147	CcSEcCtD
Methadone—Vomiting—Sunitinib—pancreatic cancer	6.64e-05	0.00145	CcSEcCtD
Methadone—Body temperature increased—Gemcitabine—pancreatic cancer	6.62e-05	0.00144	CcSEcCtD
Methadone—Rash—Sunitinib—pancreatic cancer	6.58e-05	0.00144	CcSEcCtD
Methadone—Dermatitis—Sunitinib—pancreatic cancer	6.58e-05	0.00143	CcSEcCtD
Methadone—Urticaria—Fluorouracil—pancreatic cancer	6.54e-05	0.00143	CcSEcCtD
Methadone—Headache—Sunitinib—pancreatic cancer	6.54e-05	0.00143	CcSEcCtD
Methadone—Syncope—Docetaxel—pancreatic cancer	6.53e-05	0.00142	CcSEcCtD
Methadone—Body temperature increased—Fluorouracil—pancreatic cancer	6.51e-05	0.00142	CcSEcCtD
Methadone—Palpitations—Docetaxel—pancreatic cancer	6.44e-05	0.0014	CcSEcCtD
Methadone—Weight increased—Epirubicin—pancreatic cancer	6.42e-05	0.0014	CcSEcCtD
Methadone—Loss of consciousness—Docetaxel—pancreatic cancer	6.4e-05	0.0014	CcSEcCtD
Methadone—Weight decreased—Epirubicin—pancreatic cancer	6.38e-05	0.00139	CcSEcCtD
Methadone—Hypersensitivity—Irinotecan—pancreatic cancer	6.34e-05	0.00138	CcSEcCtD
Methadone—ABCB1—islet of Langerhans—pancreatic cancer	6.33e-05	0.0161	CbGeAlD
Methadone—Convulsion—Docetaxel—pancreatic cancer	6.31e-05	0.00138	CcSEcCtD
Methadone—Drowsiness—Epirubicin—pancreatic cancer	6.29e-05	0.00137	CcSEcCtD
Methadone—Nausea—Sunitinib—pancreatic cancer	6.2e-05	0.00135	CcSEcCtD
Methadone—Asthenia—Irinotecan—pancreatic cancer	6.17e-05	0.00135	CcSEcCtD
Methadone—Hypersensitivity—Fluorouracil—pancreatic cancer	6.07e-05	0.00132	CcSEcCtD
Methadone—Dry mouth—Docetaxel—pancreatic cancer	6.06e-05	0.00132	CcSEcCtD
Methadone—Sweating—Epirubicin—pancreatic cancer	6.03e-05	0.00131	CcSEcCtD
Methadone—Asthenia—Gemcitabine—pancreatic cancer	6.01e-05	0.00131	CcSEcCtD
Methadone—Confusional state—Docetaxel—pancreatic cancer	5.99e-05	0.00131	CcSEcCtD
Methadone—Anaphylactic shock—Docetaxel—pancreatic cancer	5.94e-05	0.0013	CcSEcCtD
Methadone—Oedema—Docetaxel—pancreatic cancer	5.94e-05	0.0013	CcSEcCtD
Methadone—Weight increased—Doxorubicin—pancreatic cancer	5.94e-05	0.00129	CcSEcCtD
Methadone—Pruritus—Gemcitabine—pancreatic cancer	5.93e-05	0.00129	CcSEcCtD
Methadone—Weight decreased—Doxorubicin—pancreatic cancer	5.9e-05	0.00129	CcSEcCtD
Methadone—Diarrhoea—Irinotecan—pancreatic cancer	5.88e-05	0.00128	CcSEcCtD
Methadone—Shock—Docetaxel—pancreatic cancer	5.85e-05	0.00128	CcSEcCtD
Methadone—Pruritus—Fluorouracil—pancreatic cancer	5.83e-05	0.00127	CcSEcCtD
Methadone—Thrombocytopenia—Docetaxel—pancreatic cancer	5.82e-05	0.00127	CcSEcCtD
Methadone—Drowsiness—Doxorubicin—pancreatic cancer	5.82e-05	0.00127	CcSEcCtD
Methadone—Tachycardia—Docetaxel—pancreatic cancer	5.8e-05	0.00126	CcSEcCtD
Methadone—Bradycardia—Epirubicin—pancreatic cancer	5.74e-05	0.00125	CcSEcCtD
Methadone—Diarrhoea—Gemcitabine—pancreatic cancer	5.73e-05	0.00125	CcSEcCtD
Methadone—Dizziness—Irinotecan—pancreatic cancer	5.69e-05	0.00124	CcSEcCtD
Methadone—Anorexia—Docetaxel—pancreatic cancer	5.67e-05	0.00124	CcSEcCtD
Methadone—Diarrhoea—Fluorouracil—pancreatic cancer	5.63e-05	0.00123	CcSEcCtD
Methadone—Sweating—Doxorubicin—pancreatic cancer	5.58e-05	0.00122	CcSEcCtD
Methadone—Hypotension—Docetaxel—pancreatic cancer	5.55e-05	0.00121	CcSEcCtD
Methadone—Vomiting—Irinotecan—pancreatic cancer	5.47e-05	0.00119	CcSEcCtD
Methadone—Dizziness—Fluorouracil—pancreatic cancer	5.45e-05	0.00119	CcSEcCtD
Methadone—Visual impairment—Epirubicin—pancreatic cancer	5.44e-05	0.00119	CcSEcCtD
Methadone—Rash—Irinotecan—pancreatic cancer	5.42e-05	0.00118	CcSEcCtD
Methadone—Dermatitis—Irinotecan—pancreatic cancer	5.42e-05	0.00118	CcSEcCtD
Methadone—Headache—Irinotecan—pancreatic cancer	5.39e-05	0.00117	CcSEcCtD
Methadone—Insomnia—Docetaxel—pancreatic cancer	5.38e-05	0.00117	CcSEcCtD
Methadone—CYP3A4—digestive system—pancreatic cancer	5.37e-05	0.0136	CbGeAlD
Methadone—Vomiting—Gemcitabine—pancreatic cancer	5.33e-05	0.00116	CcSEcCtD
Methadone—Bradycardia—Doxorubicin—pancreatic cancer	5.32e-05	0.00116	CcSEcCtD
Methadone—Somnolence—Docetaxel—pancreatic cancer	5.28e-05	0.00115	CcSEcCtD
Methadone—CYP2D6—digestive system—pancreatic cancer	5.28e-05	0.0134	CbGeAlD
Methadone—Rash—Gemcitabine—pancreatic cancer	5.28e-05	0.00115	CcSEcCtD
Methadone—Dermatitis—Gemcitabine—pancreatic cancer	5.28e-05	0.00115	CcSEcCtD
Methadone—Headache—Gemcitabine—pancreatic cancer	5.25e-05	0.00114	CcSEcCtD
Methadone—Flushing—Epirubicin—pancreatic cancer	5.24e-05	0.00114	CcSEcCtD
Methadone—Vomiting—Fluorouracil—pancreatic cancer	5.24e-05	0.00114	CcSEcCtD
Methadone—Rash—Fluorouracil—pancreatic cancer	5.19e-05	0.00113	CcSEcCtD
Methadone—Dermatitis—Fluorouracil—pancreatic cancer	5.19e-05	0.00113	CcSEcCtD
Methadone—Decreased appetite—Docetaxel—pancreatic cancer	5.17e-05	0.00113	CcSEcCtD
Methadone—Headache—Fluorouracil—pancreatic cancer	5.16e-05	0.00112	CcSEcCtD
Methadone—Nausea—Irinotecan—pancreatic cancer	5.11e-05	0.00111	CcSEcCtD
Methadone—Pain—Docetaxel—pancreatic cancer	5.08e-05	0.00111	CcSEcCtD
Methadone—Constipation—Docetaxel—pancreatic cancer	5.08e-05	0.00111	CcSEcCtD
Methadone—Chills—Epirubicin—pancreatic cancer	5.06e-05	0.0011	CcSEcCtD
Methadone—Arrhythmia—Epirubicin—pancreatic cancer	5.04e-05	0.0011	CcSEcCtD
Methadone—Visual impairment—Doxorubicin—pancreatic cancer	5.03e-05	0.0011	CcSEcCtD
Methadone—Nausea—Gemcitabine—pancreatic cancer	4.98e-05	0.00108	CcSEcCtD
Methadone—Erythema—Epirubicin—pancreatic cancer	4.91e-05	0.00107	CcSEcCtD
Methadone—Feeling abnormal—Docetaxel—pancreatic cancer	4.9e-05	0.00107	CcSEcCtD
Methadone—Nausea—Fluorouracil—pancreatic cancer	4.89e-05	0.00107	CcSEcCtD
Methadone—Gastrointestinal pain—Docetaxel—pancreatic cancer	4.86e-05	0.00106	CcSEcCtD
Methadone—Flushing—Doxorubicin—pancreatic cancer	4.85e-05	0.00106	CcSEcCtD
Methadone—Muscle spasms—Epirubicin—pancreatic cancer	4.72e-05	0.00103	CcSEcCtD
Methadone—Abdominal pain—Docetaxel—pancreatic cancer	4.7e-05	0.00102	CcSEcCtD
Methadone—Body temperature increased—Docetaxel—pancreatic cancer	4.7e-05	0.00102	CcSEcCtD
Methadone—Chills—Doxorubicin—pancreatic cancer	4.69e-05	0.00102	CcSEcCtD
Methadone—Arrhythmia—Doxorubicin—pancreatic cancer	4.66e-05	0.00102	CcSEcCtD
Methadone—Erythema—Doxorubicin—pancreatic cancer	4.55e-05	0.000991	CcSEcCtD
Methadone—Agitation—Epirubicin—pancreatic cancer	4.51e-05	0.000984	CcSEcCtD
Methadone—ABCB1—pancreas—pancreatic cancer	4.45e-05	0.0113	CbGeAlD
Methadone—Vertigo—Epirubicin—pancreatic cancer	4.41e-05	0.000962	CcSEcCtD
Methadone—Syncope—Epirubicin—pancreatic cancer	4.41e-05	0.000961	CcSEcCtD
Methadone—Hypersensitivity—Docetaxel—pancreatic cancer	4.38e-05	0.000955	CcSEcCtD
Methadone—Muscle spasms—Doxorubicin—pancreatic cancer	4.37e-05	0.000953	CcSEcCtD
Methadone—Palpitations—Epirubicin—pancreatic cancer	4.34e-05	0.000947	CcSEcCtD
Methadone—Loss of consciousness—Epirubicin—pancreatic cancer	4.32e-05	0.000941	CcSEcCtD
Methadone—Asthenia—Docetaxel—pancreatic cancer	4.26e-05	0.00093	CcSEcCtD
Methadone—Convulsion—Epirubicin—pancreatic cancer	4.26e-05	0.000928	CcSEcCtD
Methadone—Pruritus—Docetaxel—pancreatic cancer	4.21e-05	0.000917	CcSEcCtD
Methadone—Agitation—Doxorubicin—pancreatic cancer	4.18e-05	0.000911	CcSEcCtD
Methadone—Anxiety—Epirubicin—pancreatic cancer	4.17e-05	0.000909	CcSEcCtD
Methadone—Dry mouth—Epirubicin—pancreatic cancer	4.09e-05	0.000892	CcSEcCtD
Methadone—Vertigo—Doxorubicin—pancreatic cancer	4.08e-05	0.00089	CcSEcCtD
Methadone—Syncope—Doxorubicin—pancreatic cancer	4.08e-05	0.000889	CcSEcCtD
Methadone—Diarrhoea—Docetaxel—pancreatic cancer	4.07e-05	0.000887	CcSEcCtD
Methadone—Confusional state—Epirubicin—pancreatic cancer	4.04e-05	0.000881	CcSEcCtD
Methadone—Palpitations—Doxorubicin—pancreatic cancer	4.02e-05	0.000876	CcSEcCtD
Methadone—Anaphylactic shock—Epirubicin—pancreatic cancer	4.01e-05	0.000874	CcSEcCtD
Methadone—Oedema—Epirubicin—pancreatic cancer	4.01e-05	0.000874	CcSEcCtD
Methadone—Loss of consciousness—Doxorubicin—pancreatic cancer	4e-05	0.000871	CcSEcCtD
Methadone—Shock—Epirubicin—pancreatic cancer	3.94e-05	0.00086	CcSEcCtD
Methadone—Convulsion—Doxorubicin—pancreatic cancer	3.94e-05	0.000859	CcSEcCtD
Methadone—Dizziness—Docetaxel—pancreatic cancer	3.93e-05	0.000857	CcSEcCtD
Methadone—Thrombocytopenia—Epirubicin—pancreatic cancer	3.93e-05	0.000856	CcSEcCtD
Methadone—Tachycardia—Epirubicin—pancreatic cancer	3.91e-05	0.000853	CcSEcCtD
Methadone—Hyperhidrosis—Epirubicin—pancreatic cancer	3.88e-05	0.000845	CcSEcCtD
Methadone—Anxiety—Doxorubicin—pancreatic cancer	3.86e-05	0.000841	CcSEcCtD
Methadone—Anorexia—Epirubicin—pancreatic cancer	3.82e-05	0.000833	CcSEcCtD
Methadone—ABCB1—digestive system—pancreatic cancer	3.8e-05	0.00966	CbGeAlD
Methadone—Dry mouth—Doxorubicin—pancreatic cancer	3.78e-05	0.000825	CcSEcCtD
Methadone—Vomiting—Docetaxel—pancreatic cancer	3.78e-05	0.000824	CcSEcCtD
Methadone—Rash—Docetaxel—pancreatic cancer	3.75e-05	0.000817	CcSEcCtD
Methadone—Hypotension—Epirubicin—pancreatic cancer	3.75e-05	0.000817	CcSEcCtD
Methadone—Dermatitis—Docetaxel—pancreatic cancer	3.74e-05	0.000816	CcSEcCtD
Methadone—Confusional state—Doxorubicin—pancreatic cancer	3.74e-05	0.000816	CcSEcCtD
Methadone—Headache—Docetaxel—pancreatic cancer	3.72e-05	0.000812	CcSEcCtD
Methadone—Oedema—Doxorubicin—pancreatic cancer	3.71e-05	0.000809	CcSEcCtD
Methadone—Anaphylactic shock—Doxorubicin—pancreatic cancer	3.71e-05	0.000809	CcSEcCtD
Methadone—Shock—Doxorubicin—pancreatic cancer	3.65e-05	0.000796	CcSEcCtD
Methadone—Thrombocytopenia—Doxorubicin—pancreatic cancer	3.63e-05	0.000792	CcSEcCtD
Methadone—Insomnia—Epirubicin—pancreatic cancer	3.63e-05	0.000791	CcSEcCtD
Methadone—Tachycardia—Doxorubicin—pancreatic cancer	3.62e-05	0.000789	CcSEcCtD
Methadone—Hyperhidrosis—Doxorubicin—pancreatic cancer	3.59e-05	0.000782	CcSEcCtD
Methadone—Somnolence—Epirubicin—pancreatic cancer	3.56e-05	0.000777	CcSEcCtD
Methadone—Anorexia—Doxorubicin—pancreatic cancer	3.54e-05	0.000771	CcSEcCtD
Methadone—Nausea—Docetaxel—pancreatic cancer	3.53e-05	0.00077	CcSEcCtD
Methadone—Decreased appetite—Epirubicin—pancreatic cancer	3.49e-05	0.00076	CcSEcCtD
Methadone—Hypotension—Doxorubicin—pancreatic cancer	3.47e-05	0.000756	CcSEcCtD
Methadone—Pain—Epirubicin—pancreatic cancer	3.43e-05	0.000748	CcSEcCtD
Methadone—Constipation—Epirubicin—pancreatic cancer	3.43e-05	0.000748	CcSEcCtD
Methadone—Insomnia—Doxorubicin—pancreatic cancer	3.36e-05	0.000732	CcSEcCtD
Methadone—Feeling abnormal—Epirubicin—pancreatic cancer	3.3e-05	0.00072	CcSEcCtD
Methadone—Somnolence—Doxorubicin—pancreatic cancer	3.3e-05	0.000719	CcSEcCtD
Methadone—Gastrointestinal pain—Epirubicin—pancreatic cancer	3.28e-05	0.000715	CcSEcCtD
Methadone—Decreased appetite—Doxorubicin—pancreatic cancer	3.22e-05	0.000703	CcSEcCtD
Methadone—Urticaria—Epirubicin—pancreatic cancer	3.19e-05	0.000694	CcSEcCtD
Methadone—Constipation—Doxorubicin—pancreatic cancer	3.17e-05	0.000692	CcSEcCtD
Methadone—Pain—Doxorubicin—pancreatic cancer	3.17e-05	0.000692	CcSEcCtD
Methadone—Abdominal pain—Epirubicin—pancreatic cancer	3.17e-05	0.000691	CcSEcCtD
Methadone—Body temperature increased—Epirubicin—pancreatic cancer	3.17e-05	0.000691	CcSEcCtD
Methadone—Feeling abnormal—Doxorubicin—pancreatic cancer	3.06e-05	0.000667	CcSEcCtD
Methadone—Gastrointestinal pain—Doxorubicin—pancreatic cancer	3.03e-05	0.000661	CcSEcCtD
Methadone—Hypersensitivity—Epirubicin—pancreatic cancer	2.95e-05	0.000644	CcSEcCtD
Methadone—Urticaria—Doxorubicin—pancreatic cancer	2.95e-05	0.000643	CcSEcCtD
Methadone—Body temperature increased—Doxorubicin—pancreatic cancer	2.93e-05	0.000639	CcSEcCtD
Methadone—Abdominal pain—Doxorubicin—pancreatic cancer	2.93e-05	0.000639	CcSEcCtD
Methadone—Asthenia—Epirubicin—pancreatic cancer	2.88e-05	0.000627	CcSEcCtD
Methadone—Pruritus—Epirubicin—pancreatic cancer	2.84e-05	0.000618	CcSEcCtD
Methadone—Diarrhoea—Epirubicin—pancreatic cancer	2.74e-05	0.000598	CcSEcCtD
Methadone—Hypersensitivity—Doxorubicin—pancreatic cancer	2.73e-05	0.000596	CcSEcCtD
Methadone—Asthenia—Doxorubicin—pancreatic cancer	2.66e-05	0.00058	CcSEcCtD
Methadone—Dizziness—Epirubicin—pancreatic cancer	2.65e-05	0.000578	CcSEcCtD
Methadone—Pruritus—Doxorubicin—pancreatic cancer	2.62e-05	0.000572	CcSEcCtD
Methadone—Vomiting—Epirubicin—pancreatic cancer	2.55e-05	0.000556	CcSEcCtD
Methadone—Diarrhoea—Doxorubicin—pancreatic cancer	2.54e-05	0.000553	CcSEcCtD
Methadone—Rash—Epirubicin—pancreatic cancer	2.53e-05	0.000551	CcSEcCtD
Methadone—Dermatitis—Epirubicin—pancreatic cancer	2.53e-05	0.000551	CcSEcCtD
Methadone—Headache—Epirubicin—pancreatic cancer	2.51e-05	0.000548	CcSEcCtD
Methadone—Dizziness—Doxorubicin—pancreatic cancer	2.45e-05	0.000535	CcSEcCtD
Methadone—Nausea—Epirubicin—pancreatic cancer	2.38e-05	0.000519	CcSEcCtD
Methadone—Vomiting—Doxorubicin—pancreatic cancer	2.36e-05	0.000514	CcSEcCtD
Methadone—Rash—Doxorubicin—pancreatic cancer	2.34e-05	0.00051	CcSEcCtD
Methadone—Dermatitis—Doxorubicin—pancreatic cancer	2.34e-05	0.00051	CcSEcCtD
Methadone—Headache—Doxorubicin—pancreatic cancer	2.32e-05	0.000507	CcSEcCtD
Methadone—Nausea—Doxorubicin—pancreatic cancer	2.2e-05	0.00048	CcSEcCtD
Methadone—CYP2C18—Metabolism—PTGS2—pancreatic cancer	3.03e-06	0.000175	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—EGF—pancreatic cancer	3.02e-06	0.000174	CbGpPWpGaD
Methadone—OPRD1—Signaling by GPCR—KRAS—pancreatic cancer	2.99e-06	0.000173	CbGpPWpGaD
Methadone—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—pancreatic cancer	2.97e-06	0.000171	CbGpPWpGaD
Methadone—CYP19A1—Metabolism—PPARG—pancreatic cancer	2.95e-06	0.00017	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—APOE—pancreatic cancer	2.94e-06	0.00017	CbGpPWpGaD
Methadone—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	2.93e-06	0.000169	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—HIF1A—pancreatic cancer	2.93e-06	0.000169	CbGpPWpGaD
Methadone—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	2.93e-06	0.000169	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—TSC2—pancreatic cancer	2.92e-06	0.000168	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—CD44—pancreatic cancer	2.92e-06	0.000168	CbGpPWpGaD
Methadone—CYP1A2—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	2.87e-06	0.000166	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—APOE—pancreatic cancer	2.86e-06	0.000165	CbGpPWpGaD
Methadone—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	2.86e-06	0.000165	CbGpPWpGaD
Methadone—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	2.83e-06	0.000163	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—GLP1R—pancreatic cancer	2.81e-06	0.000162	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—KDR—pancreatic cancer	2.8e-06	0.000161	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—GCG—pancreatic cancer	2.8e-06	0.000161	CbGpPWpGaD
Methadone—OPRK1—Signaling by GPCR—EGFR—pancreatic cancer	2.78e-06	0.00016	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—DPYD—pancreatic cancer	2.76e-06	0.000159	CbGpPWpGaD
Methadone—OPRD1—Signaling by GPCR—PIK3CA—pancreatic cancer	2.75e-06	0.000159	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—TYMP—pancreatic cancer	2.69e-06	0.000155	CbGpPWpGaD
Methadone—CYP19A1—Metabolism—PIK3CD—pancreatic cancer	2.68e-06	0.000155	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—PIK3CD—pancreatic cancer	2.68e-06	0.000155	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—TYMS—pancreatic cancer	2.67e-06	0.000154	CbGpPWpGaD
Methadone—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	2.67e-06	0.000154	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—PIK3CB—pancreatic cancer	2.67e-06	0.000154	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—NFKBIA—pancreatic cancer	2.66e-06	0.000154	CbGpPWpGaD
Methadone—OPRK1—GPCR downstream signaling—PIK3CA—pancreatic cancer	2.66e-06	0.000153	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—PIK3CG—pancreatic cancer	2.65e-06	0.000153	CbGpPWpGaD
Methadone—CYP2C18—Metabolism—PTEN—pancreatic cancer	2.64e-06	0.000152	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—NOTCH1—pancreatic cancer	2.64e-06	0.000152	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—STK11—pancreatic cancer	2.63e-06	0.000152	CbGpPWpGaD
Methadone—OPRK1—Signaling by GPCR—KRAS—pancreatic cancer	2.63e-06	0.000152	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—SLC2A2—pancreatic cancer	2.62e-06	0.000151	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—TYMS—pancreatic cancer	2.61e-06	0.000151	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—CD44—pancreatic cancer	2.6e-06	0.00015	CbGpPWpGaD
Methadone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	2.59e-06	0.00015	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—PIK3CG—pancreatic cancer	2.58e-06	0.000149	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—NRAS—pancreatic cancer	2.58e-06	0.000149	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—CXCL8—pancreatic cancer	2.56e-06	0.000148	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—PPARG—pancreatic cancer	2.56e-06	0.000148	CbGpPWpGaD
Methadone—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	2.55e-06	0.000147	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—EGF—pancreatic cancer	2.55e-06	0.000147	CbGpPWpGaD
Methadone—OPRD1—Signaling by GPCR—HRAS—pancreatic cancer	2.55e-06	0.000147	CbGpPWpGaD
Methadone—ABCB1—Metabolism—CD44—pancreatic cancer	2.54e-06	0.000147	CbGpPWpGaD
Methadone—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	2.53e-06	0.000146	CbGpPWpGaD
Methadone—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	2.5e-06	0.000144	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—GCG—pancreatic cancer	2.5e-06	0.000144	CbGpPWpGaD
Methadone—OPRD1—GPCR downstream signaling—AKT1—pancreatic cancer	2.47e-06	0.000143	CbGpPWpGaD
Methadone—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	2.47e-06	0.000142	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—CASP3—pancreatic cancer	2.45e-06	0.000141	CbGpPWpGaD
Methadone—ABCB1—Metabolism—GCG—pancreatic cancer	2.44e-06	0.000141	CbGpPWpGaD
Methadone—OPRK1—Signaling by GPCR—PIK3CA—pancreatic cancer	2.41e-06	0.000139	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—CD44—pancreatic cancer	2.4e-06	0.000138	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—CCND1—pancreatic cancer	2.39e-06	0.000138	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—CD44—pancreatic cancer	2.37e-06	0.000137	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—CTNNB1—pancreatic cancer	2.36e-06	0.000136	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—EGFR—pancreatic cancer	2.35e-06	0.000136	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—STK11—pancreatic cancer	2.35e-06	0.000135	CbGpPWpGaD
Methadone—CYP19A1—Metabolism—PIK3CB—pancreatic cancer	2.34e-06	0.000135	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—PIK3CB—pancreatic cancer	2.34e-06	0.000135	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—PIK3CD—pancreatic cancer	2.33e-06	0.000135	CbGpPWpGaD
Methadone—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	2.33e-06	0.000134	CbGpPWpGaD
Methadone—CYP19A1—Metabolism—PTGS2—pancreatic cancer	2.32e-06	0.000134	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—MMP9—pancreatic cancer	2.32e-06	0.000134	CbGpPWpGaD
Methadone—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	2.3e-06	0.000133	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—PTEN—pancreatic cancer	2.3e-06	0.000133	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—GCG—pancreatic cancer	2.3e-06	0.000132	CbGpPWpGaD
Methadone—ABCB1—Metabolism—STK11—pancreatic cancer	2.29e-06	0.000132	CbGpPWpGaD
Methadone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	2.28e-06	0.000132	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—GCG—pancreatic cancer	2.28e-06	0.000131	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—PIK3CD—pancreatic cancer	2.27e-06	0.000131	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—TYMS—pancreatic cancer	2.26e-06	0.000131	CbGpPWpGaD
Methadone—OPRD1—Signaling by GPCR—AKT1—pancreatic cancer	2.25e-06	0.00013	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—CXCL8—pancreatic cancer	2.25e-06	0.00013	CbGpPWpGaD
Methadone—OPRM1—GPCR downstream signaling—PIK3CA—pancreatic cancer	2.25e-06	0.00013	CbGpPWpGaD
Methadone—OPRK1—Signaling by GPCR—HRAS—pancreatic cancer	2.23e-06	0.000129	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—KRAS—pancreatic cancer	2.22e-06	0.000128	CbGpPWpGaD
Methadone—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	2.2e-06	0.000127	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—APOE—pancreatic cancer	2.17e-06	0.000125	CbGpPWpGaD
Methadone—OPRK1—GPCR downstream signaling—AKT1—pancreatic cancer	2.17e-06	0.000125	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—GLP1R—pancreatic cancer	2.17e-06	0.000125	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—STK11—pancreatic cancer	2.16e-06	0.000125	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—CASP3—pancreatic cancer	2.15e-06	0.000124	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—STK11—pancreatic cancer	2.14e-06	0.000123	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—SRC—pancreatic cancer	2.14e-06	0.000123	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—DPYD—pancreatic cancer	2.13e-06	0.000123	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—APOE—pancreatic cancer	2.12e-06	0.000123	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—CCND1—pancreatic cancer	2.09e-06	0.000121	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—VEGFA—pancreatic cancer	2.08e-06	0.00012	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—CTNNB1—pancreatic cancer	2.07e-06	0.00012	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—STAT3—pancreatic cancer	2.06e-06	0.000119	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—NRAS—pancreatic cancer	2.06e-06	0.000119	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—PIK3CA—pancreatic cancer	2.04e-06	0.000118	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—PIK3CB—pancreatic cancer	2.03e-06	0.000117	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—MMP9—pancreatic cancer	2.03e-06	0.000117	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—CD44—pancreatic cancer	2.03e-06	0.000117	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—SLC2A2—pancreatic cancer	2.02e-06	0.000117	CbGpPWpGaD
Methadone—CYP19A1—Metabolism—PTEN—pancreatic cancer	2.02e-06	0.000117	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—PTEN—pancreatic cancer	2.02e-06	0.000117	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—TYMS—pancreatic cancer	2.02e-06	0.000117	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—PTGS2—pancreatic cancer	2.01e-06	0.000116	CbGpPWpGaD
Methadone—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	2.01e-06	0.000116	CbGpPWpGaD
Methadone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	1.99e-06	0.000115	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—PIK3CB—pancreatic cancer	1.98e-06	0.000114	CbGpPWpGaD
Methadone—ABCB1—Metabolism—TYMS—pancreatic cancer	1.97e-06	0.000114	CbGpPWpGaD
Methadone—OPRK1—Signaling by GPCR—AKT1—pancreatic cancer	1.97e-06	0.000114	CbGpPWpGaD
Methadone—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	1.97e-06	0.000114	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—PIK3CG—pancreatic cancer	1.96e-06	0.000113	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—GCG—pancreatic cancer	1.95e-06	0.000112	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—PIK3CG—pancreatic cancer	1.92e-06	0.000111	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—MYC—pancreatic cancer	1.91e-06	0.00011	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—TGFB1—pancreatic cancer	1.91e-06	0.00011	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—CXCL8—pancreatic cancer	1.9e-06	0.00011	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—PPARG—pancreatic cancer	1.89e-06	0.000109	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—HRAS—pancreatic cancer	1.89e-06	0.000109	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—SRC—pancreatic cancer	1.87e-06	0.000108	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—EGFR—pancreatic cancer	1.87e-06	0.000108	CbGpPWpGaD
Methadone—CYP2C18—Metabolism—PIK3CA—pancreatic cancer	1.86e-06	0.000108	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—TYMS—pancreatic cancer	1.86e-06	0.000107	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—PPARG—pancreatic cancer	1.85e-06	0.000107	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—TYMS—pancreatic cancer	1.84e-06	0.000106	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—APOE—pancreatic cancer	1.84e-06	0.000106	CbGpPWpGaD
Methadone—OPRM1—GPCR downstream signaling—AKT1—pancreatic cancer	1.83e-06	0.000106	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—STK11—pancreatic cancer	1.83e-06	0.000106	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—VEGFA—pancreatic cancer	1.82e-06	0.000105	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—CASP3—pancreatic cancer	1.82e-06	0.000105	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—STAT3—pancreatic cancer	1.81e-06	0.000104	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—NRAS—pancreatic cancer	1.8e-06	0.000104	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—KRAS—pancreatic cancer	1.77e-06	0.000102	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—CCND1—pancreatic cancer	1.77e-06	0.000102	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—PTEN—pancreatic cancer	1.76e-06	0.000101	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—CTNNB1—pancreatic cancer	1.75e-06	0.000101	CbGpPWpGaD
Methadone—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	1.74e-06	0.0001	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—PIK3CD—pancreatic cancer	1.72e-06	9.95e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—MMP9—pancreatic cancer	1.72e-06	9.91e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	1.72e-06	9.91e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—PTEN—pancreatic cancer	1.71e-06	9.85e-05	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—PIK3CD—pancreatic cancer	1.69e-06	9.72e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—MYC—pancreatic cancer	1.68e-06	9.69e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—TGFB1—pancreatic cancer	1.67e-06	9.66e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—AKT1—pancreatic cancer	1.67e-06	9.61e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—PIK3CG—pancreatic cancer	1.66e-06	9.58e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—APOE—pancreatic cancer	1.64e-06	9.48e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—EGFR—pancreatic cancer	1.64e-06	9.47e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—PIK3CA—pancreatic cancer	1.63e-06	9.38e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—APOE—pancreatic cancer	1.6e-06	9.25e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—PPARG—pancreatic cancer	1.6e-06	9.25e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—SRC—pancreatic cancer	1.58e-06	9.14e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—TYMS—pancreatic cancer	1.57e-06	9.08e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—TP53—pancreatic cancer	1.57e-06	9.07e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—CD44—pancreatic cancer	1.57e-06	9.04e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	1.55e-06	8.97e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—KRAS—pancreatic cancer	1.55e-06	8.95e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—VEGFA—pancreatic cancer	1.54e-06	8.9e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—STAT3—pancreatic cancer	1.53e-06	8.81e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—NRAS—pancreatic cancer	1.52e-06	8.79e-05	CbGpPWpGaD
Methadone—CYP2C18—Metabolism—AKT1—pancreatic cancer	1.52e-06	8.78e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—APOE—pancreatic cancer	1.51e-06	8.72e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—HRAS—pancreatic cancer	1.5e-06	8.68e-05	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—PIK3CB—pancreatic cancer	1.5e-06	8.67e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—GCG—pancreatic cancer	1.5e-06	8.66e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—APOE—pancreatic cancer	1.5e-06	8.64e-05	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—PTGS2—pancreatic cancer	1.49e-06	8.59e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—PIK3CG—pancreatic cancer	1.48e-06	8.55e-05	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—PIK3CB—pancreatic cancer	1.47e-06	8.48e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—PIK3CD—pancreatic cancer	1.46e-06	8.42e-05	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—PTGS2—pancreatic cancer	1.46e-06	8.4e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—PIK3CG—pancreatic cancer	1.45e-06	8.35e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—PPARG—pancreatic cancer	1.43e-06	8.25e-05	CbGpPWpGaD
Methadone—CYP19A1—Metabolism—PIK3CA—pancreatic cancer	1.43e-06	8.23e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—PIK3CA—pancreatic cancer	1.42e-06	8.22e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—MYC—pancreatic cancer	1.42e-06	8.19e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	1.42e-06	8.18e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—TGFB1—pancreatic cancer	1.42e-06	8.17e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—STK11—pancreatic cancer	1.41e-06	8.14e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—PPARG—pancreatic cancer	1.4e-06	8.06e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—EGFR—pancreatic cancer	1.39e-06	8.01e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—TP53—pancreatic cancer	1.38e-06	7.95e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—PIK3CG—pancreatic cancer	1.36e-06	7.87e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—PIK3CG—pancreatic cancer	1.35e-06	7.8e-05	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—AKT1—pancreatic cancer	1.33e-06	7.66e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—HRAS—pancreatic cancer	1.32e-06	7.61e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—PPARG—pancreatic cancer	1.32e-06	7.59e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—KRAS—pancreatic cancer	1.31e-06	7.56e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—PPARG—pancreatic cancer	1.3e-06	7.53e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—PIK3CD—pancreatic cancer	1.3e-06	7.52e-05	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—PTEN—pancreatic cancer	1.3e-06	7.49e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—APOE—pancreatic cancer	1.28e-06	7.38e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—PIK3CB—pancreatic cancer	1.27e-06	7.34e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—PIK3CD—pancreatic cancer	1.27e-06	7.34e-05	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—PTEN—pancreatic cancer	1.27e-06	7.32e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—PTGS2—pancreatic cancer	1.26e-06	7.27e-05	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—PIK3CA—pancreatic cancer	1.24e-06	7.15e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—TYMS—pancreatic cancer	1.21e-06	7.01e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	1.21e-06	6.99e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—PIK3CA—pancreatic cancer	1.2e-06	6.95e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—PIK3CD—pancreatic cancer	1.2e-06	6.91e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—PIK3CD—pancreatic cancer	1.19e-06	6.85e-05	CbGpPWpGaD
Methadone—CYP19A1—Metabolism—AKT1—pancreatic cancer	1.17e-06	6.72e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—TP53—pancreatic cancer	1.17e-06	6.72e-05	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—AKT1—pancreatic cancer	1.16e-06	6.72e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—PIK3CG—pancreatic cancer	1.15e-06	6.66e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—PIK3CB—pancreatic cancer	1.14e-06	6.55e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—PTGS2—pancreatic cancer	1.13e-06	6.49e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—PPARG—pancreatic cancer	1.11e-06	6.43e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—HRAS—pancreatic cancer	1.11e-06	6.43e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—PIK3CB—pancreatic cancer	1.11e-06	6.4e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—PTEN—pancreatic cancer	1.1e-06	6.34e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—PTGS2—pancreatic cancer	1.1e-06	6.34e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—PIK3CB—pancreatic cancer	1.04e-06	6.03e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—PIK3CB—pancreatic cancer	1.04e-06	5.97e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—PTGS2—pancreatic cancer	1.03e-06	5.97e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—PTGS2—pancreatic cancer	1.03e-06	5.92e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—PIK3CD—pancreatic cancer	1.02e-06	5.86e-05	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—AKT1—pancreatic cancer	1.01e-06	5.84e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—APOE—pancreatic cancer	9.87e-07	5.7e-05	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—AKT1—pancreatic cancer	9.84e-07	5.68e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—PTEN—pancreatic cancer	9.81e-07	5.66e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—PTEN—pancreatic cancer	9.58e-07	5.53e-05	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—PIK3CA—pancreatic cancer	9.16e-07	5.29e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—PTEN—pancreatic cancer	9.03e-07	5.21e-05	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—PIK3CA—pancreatic cancer	8.95e-07	5.17e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—PTEN—pancreatic cancer	8.95e-07	5.16e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	8.91e-07	5.14e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—PIK3CB—pancreatic cancer	8.85e-07	5.11e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—PTGS2—pancreatic cancer	8.77e-07	5.06e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—PPARG—pancreatic cancer	8.6e-07	4.96e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	7.83e-07	4.52e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—PIK3CA—pancreatic cancer	7.76e-07	4.48e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—PTEN—pancreatic cancer	7.65e-07	4.41e-05	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—AKT1—pancreatic cancer	7.48e-07	4.32e-05	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—AKT1—pancreatic cancer	7.31e-07	4.22e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—PIK3CA—pancreatic cancer	6.92e-07	3.99e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	6.83e-07	3.94e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—PTGS2—pancreatic cancer	6.77e-07	3.9e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—PIK3CA—pancreatic cancer	6.76e-07	3.9e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—PIK3CA—pancreatic cancer	6.37e-07	3.67e-05	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—AKT1—pancreatic cancer	6.34e-07	3.66e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—PIK3CA—pancreatic cancer	6.31e-07	3.64e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—PTEN—pancreatic cancer	5.9e-07	3.4e-05	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—AKT1—pancreatic cancer	5.66e-07	3.26e-05	CbGpPWpGaD
Methadone—ABCB1—Metabolism—AKT1—pancreatic cancer	5.52e-07	3.18e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—PIK3CA—pancreatic cancer	5.39e-07	3.11e-05	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—AKT1—pancreatic cancer	5.2e-07	3e-05	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—AKT1—pancreatic cancer	5.16e-07	2.98e-05	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—AKT1—pancreatic cancer	4.41e-07	2.54e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	4.16e-07	2.4e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—AKT1—pancreatic cancer	3.4e-07	1.96e-05	CbGpPWpGaD
